Actinium Pharmaceuticals Introduces Groundbreaking HER3-Targeted Treatment at EANM 2026

Actinium Pharmaceuticals, a frontrunner in innovative cancer therapies, recently unveiled significant findings regarding ATNM-400 at the EANM 2026 conference in Vienna, Austria. This pioneering treatment represents a first-in-human radiotherapy targeting HER3, which is a known contributor to tumor progression and resistance to traditional prostate cancer therapies.

Promising Initial Results

The results presented highlighted the initial safety and effectiveness of ATNM-400, a groundbreaking approach aimed at treating metastatic castration-resistant prostate cancer (mCRPC). During the Phase 1 trial, the drug demonstrated tumor uptake and retention through HER3-targeted imaging, supporting its ability to offer sustained alpha radiation to cancer cells. The data indicated that ATNM-400 has the potential to provide a much-needed alternative for patients who currently have limited treatment options, particularly those with PSMA (Prostate-Specific Membrane Antigen) low or PSMA-negative diseases.

Initial Safety Profile

For safety assessments, the first dose level of ATNM-400, set at 1.0 µCi/kg, was administered to three patients with previously treated mCRPC. Remarkably, no dose-limiting toxicities, xerostomia (dry mouth), or significant hematological adverse effects (Grades 3/4) were reported. This favorable safety profile prompted the clinical team to escalate the dose to 1.5 µCi/kg, marking a significant advancement in trials aiming to establish an effective treatment protocol.

Ongoing Trial and Further Research Opportunities

The initial cohort's responses have sparked enthusiasm among clinical researchers, with the ongoing investigations about how ATNM-400 can be combined with other established prostate cancer therapies. Sandesh Seth, the CEO of Actinium, expressed excitement about the early-stage findings, emphasizing HER3's role in tumor survival and progression as a meaningful target. The Company aims to expand its focus beyond just localized prostate cancer but also explore its potential in treating various solid tumors with high HER3 expression.

The Unique Mechanism of ATNM-400

ATNM-400 represents a new class of targeted therapy that combines a monoclonal antibody called barecetamab with the alpha-emitting isotope Actinium-225. This combination provides the dual advantage of targeted therapy and high-energy alpha radiation. The theranostic approach, utilizing Zirconium-89 (¹⁸⁹Zr) labeled imaging, allows for non-invasive visualization of drug distribution, offering essential data that could drive further therapeutic development.

The intriguing preclinical findings of ATNM-400 suggest it could be effective not only in prostate cancer but also in other types of cancers, such as non-small cell lung cancer and breast cancer, due to HER3's expression. Its strategy of focusing on HER3 instead of PSMA opens doors for exploring treatment in various patient populations that have been previously underserved.

Conclusion

As Actinium Pharmaceuticals moves forward with the clinical development of ATNM-400, the initial results from the Phase 1 study serve as a beacon of hope for both patients and healthcare providers involved in the fight against advanced prostate cancer. With ongoing trials and a clear focus on broadening the scope of HER3-targeted therapy, the future of cancer treatment could soon see a transformational shift. Actinium continues to showcase their commitment to advancing cancer care and innovating radiotherapy solutions.